OABI · OmniAb, Inc.
$4.30
+0.11 (+2.63%)
At close · Aug 20
Market Cap
$609.19M
Shares
145.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.30
Open$4.19
Day$4.16–4.59
52W close$1.36–4.30
Avg vol 30d1.4M
Short int9K · 0.0% float · 3.7d
Short vol39%
Last earningsAug 6, 2026
DataSep 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+116%
above
Price vs 50-day avg
+73%
above
RSI (14)
89
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+111%
trailing
6-month return
+150%
trailing
YTD return
+132%
this year
Relative strength
+139%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -4.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
142 holders — near 3-yr low, contrarian setup
Fundamentals
Revenue growth
−29%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-37.0M
Balance sheet
$25.5M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
2026
Revenue
$32M – $36M
prior FY $18.67M
midpoint +82.1% Y/Y
Costs and operating expenses
GAAP
$84M – $88M
end of the year
Cash and cash equivalents
$37M – $41M
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Revenue
· 2025
$18M – $22M
Operating expense
· 2025
$82M – $86M
Cash
· end of 2025
$52M – $56M
Guided vs delivered
· last 1 settled
Revenue
2025
guided $18M – $22M
$18.67M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+116%
Bullish
Price vs 50-day avg
+73%
Bullish
RSI (14)
89
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -4.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
142 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $4 · 100%
Range high $4
vs 200-day avg +116%
vs 50-day avg +73%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active partners | 110 | As of June 30, 2026 | — |
|
|
|||
| active programs | 425 | As of June 30, 2026 | — |
|
|
|||
| Cash costs and operating expenses non-GAAP | $25.5M | first half of 2026 | — |
| OmniAb-derived programs in clinical development or being commercialized | 34 | As of June 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OABI
this stock
OmniAb, Inc.
|
$609.19M | +132.4% | -29.3% | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OABI | +25.4% | +110.8% | +150.0% | +117.2% | +132.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +27.3% | +107.5% | +138.8% | +115.1% | +120.6% |
Key facts
CIK
1846253
CUSIP
68218J111
13F (30d)
135 filings
134 filers
Visit website
Investor relations